
Gregor S D Reid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6016700/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A crossâ€standardized flow cytometry platform to assess phenotypic stability in precursor Bâ€cell acute lymphoblastic leukemia (Bâ€ALL) xenografts. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, 101, 57-71.	1.1	1
2	Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways. European Journal of Pharmaceutical Sciences, 2022, 176, 106234.	1.9	14
3	PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathways. Journal of Experimental and Clinical Cancer Research, 2021, 40, 96.	3.5	13
4	Vasoactive intestinal peptide promotes host defense against enteric pathogens by modulating the recruitment of group 3 innate lymphoid cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	30
5	Toll-like Receptor-3 Ligation Induces Pro-Survival Signaling in Pediatric Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3403-3403.	0.6	0
6	Ulcerative Colitis-associated <i>E. coli</i> pathobionts potentiate colitis in susceptible hosts. Gut Microbes, 2020, 12, 1847976.	4.3	26
7	Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists. Cancers, 2020, 12, 169.	1.7	5
8	MRD Xenotransplantation Prospectively Identifies Treatment-Selected Acute Lymphoblastic Leukemia Subpopulations with Relapse-Initiating Potential. Blood, 2020, 136, 12-13.	0.6	1
9	The TLR9 agonist (CNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study. Pediatric Hematology and Oncology, 2019, 36, 468-481.	0.3	12
10	Integrins and ERp57 Coordinate to Regulate Cell Surface Calreticulin in Immunogenic Cell Death. Frontiers in Oncology, 2019, 9, 411.	1.3	18
11	TLR9 limits enteric antimicrobial responses and promotes microbiotaâ€based colonisation resistance during <i>Citrobacter rodentium</i> infection. Cellular Microbiology, 2019, 21, e13026.	1.1	8
12	The nonmotor adaptor HMMR dampens Eg5-mediated forces to preserve the kinetics and integrity of chromosome segregation. Molecular Biology of the Cell, 2018, 29, 786-796.	0.9	15
13	Combination therapy with proteasome inhibitors and TLR agonists enhances tumour cell death and IL- $1\hat{I}^2$ production. Cell Death and Disease, 2018, 9, 162.	2.7	10
14	Tumor Variant Identification That Accounts for the Unique Molecular Landscape of Pediatric Malignancies. JNCI Cancer Spectrum, 2018, 2, pky079.	1.4	8
15	CD47-ligation induced cell death in T-acute lymphoblastic leukemia. Cell Death and Disease, 2018, 9, 544.	2.7	49
16	IFNâ€Î³ directly inhibits murine Bâ€cell precursor leukemiaâ€initiating cell proliferation early in life. European Journal of Immunology, 2017, 47, 892-899.	1.6	13
17	Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia. Oncology Letters, 2017, 13, 497-505.	0.8	8
18	α-Integrin expression and function modulates presentation of cell surface calreticulin. Cell Death and Disease, 2016, 7, e2268-e2268.	2.7	25

GREGOR S D REID

#	Article	IF	CITATIONS
19	Engraftment and Long-Term Survival at Low Burden of Leukemic Blasts from Primary MRD+ Human Bone Marrow in a Xenotransplant Setting. Blood, 2016, 128, 1730-1730.	0.6	0
20	Heterodimerâ€specific TLR2 stimulation results in divergent functional outcomes in Bâ€cell precursor acute lymphoblastic leukemia. European Journal of Immunology, 2015, 45, 1980-1990.	1.6	15
21	Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state. Journal of Leukocyte Biology, 2015, 98, 983-994.	1.5	32
22	Epitope Spreading Is Required for Long-Term Protection Against Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3717-3717.	0.6	0
23	Heterodimer-Specific Stimulation Of Toll-Like Receptor 2 Induces Divergent Downstream Effects In Primary Samples Of Precursor B Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 3918-3918.	0.6	9
24	A Novel Model of Immune-Mediated Disease Equilibrium in Acute Lymphoblastic Leukemia. Blood, 2012, 120, 3540-3540.	0.6	0
25	Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood, 2011, 118, e112-e117.	0.6	49
26	Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia. Blood, 2010, 116, 2140-2140.	0.6	1
27	Interferon-Â-Dependent Infiltration of Human T Cells into Neuroblastoma Tumors In vivo. Clinical Cancer Research, 2009, 15, 6602-6608.	3.2	30
28	Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. Blood, 2009, 114, 2459-2466.	0.6	36
29	Removal of Normal Competition Increases Proliferation of Pre-Leukemic Cells in a Mouse Model of Pre-B Acute Lymphoblastic Leukemia Blood, 2009, 114, 1430-1430.	0.6	0
30	Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunologic Research, 2008, 42, 84-105.	1.3	35
31	Detection of WT1-specific T cells in paediatric acute lymphoblastic leukaemia patients in first remission. British Journal of Haematology, 2008, 141, 271-273.	1.2	6
32	Targeting Notch signaling in autoimmune and lymphoproliferative disease. Blood, 2008, 111, 705-714.	0.6	68
33	mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood, 2008, 112, 2020-2023.	0.6	117
34	In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. Blood, 2007, 109, 2008-2013.	0.6	42
35	Altered Toll-Like Receptor 9 Responses in Circulating B Cells at the Onset of Extensive Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2007, 13, 386-397.	2.0	81
36	CpG Oligonucleotides Induce Anti-Leukemia Activity in a Syngeneic Murine Model of Acute Lymphoblastic Leukemia Blood, 2007, 110, 2830-2830.	0.6	0

GREGOR S D REID

#	Article	IF	CITATIONS
37	HLA-DM expression is elevated in ETV6–AML1 translocation-positive pediatric acute lymphoblastic leukemia. Leukemia Research, 2006, 30, 487-489.	0.4	10
38	In Vivo Control of Acute Lymphoblastic Leukemia by Immunostimulatory CpG Oligonucleotides Blood, 2006, 108, 1868-1868.	0.6	15
39	Immune evasion strategies of pediatric precursor-B acute lymphoblastic leukemia after allogeneic bone marrow transplantation—a case study. Leukemia Research, 2005, 29, 711-714.	0.4	7
40	Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2005, 132, 051220022257006.	1.2	23
41	CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood, 2005, 105, 3641-3647.	0.6	36
42	Progression of spontaneous autoimmune diabetes is associated with a switch in the killing mechanism used by autoreactive CTL. International Immunology, 2004, 16, 1657-1662.	1.8	17
43	The Cationic Antimicrobial Peptide LL-37 Modulates Dendritic Cell Differentiation and Dendritic Cell-Induced T Cell Polarization. Journal of Immunology, 2004, 172, 1146-1156.	0.4	392
44	Expression of the adaptor protein BLNK/SLP-65 in childhood acute lymphoblastic leukemia. Leukemia, 2004, 18, 922-925.	3.3	21
45	Primary Immunodeficiency to pneumococcal infection due to a defect in Toll-like receptor signaling. Journal of Pediatrics, 2004, 144, 512-518.	0.9	68
46	Detection of T-Cells Specific for Leukemia-Associated Antigens in Pediatric Patients with Acute Lymphoblastic Leukemia in First Complete Remission Blood, 2004, 104, 526-526.	0.6	8
47	Stimulation of Precursor-B Acute Lymphoblastic Leukemia Cells with Toll-Like Receptor Ligands Alters Their Immunogenicity Blood, 2004, 104, 1887-1887.	0.6	0
48	Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cells. Leukemia Research, 2003, 27, 1135-1142.	0.4	11
49	ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. British Journal of Haematology, 2002, 116, 266-272.	1.2	26
50	Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line. Clinical and Experimental Immunology, 2002, 129, 265-271.	1.1	19
51	ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. British Journal of Haematology, 2002, 116, 266-72.	1.2	3
52	TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nature Biotechnology, 2000, 18, 515-520.	9.4	88
53	Surrogate Antigen Processing Mediated by TAP-dependent Antigenic Peptide Secretion. Journal of Cell Biology, 1998, 140, 17-27.	2.3	8
54	Novel Peptide-Binding Proteins and Peptide Transport in Normal and TAP-Deficient Microsomes. Biochemistry, 1997, 36, 856-863.	1.2	38

#	Article	IF	CITATIONS
55	Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing Journal of Experimental Medicine, 1994, 180, 1415-1425.	4.2	88
56	The role of the ovary and nutritional signals in the regulation of fat body yolk protein gene expression in Drosophila melanogaster. Journal of Insect Physiology, 1990, 36, 471-479.	0.9	36